FDA greenlights first artificial iris in US

The FDA approved the first standalone prosthetic iris in the U.S. May 30.

Advertisement

Clinical Research Consultants’ CustomFlex Artificial Iris is a surgically implanted device for patients whose iris is missing or damaged.

The artificial iris is comprised of a thin, foldable silicone material, which can be customized and color-matched to each patient’s eyes.

Surgeons insert the iris via a small incision in the eye, and the eye’s anatomical structures hold the iris in place.

“Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye,” said Malvina Eydelman, MD, director of the division of ophthalmic and ENT devices at the FDA’s Center for Devices and Radiological Health. “Today’s approval of the first artificial iris provides a novel method to treat iris defects that reduce sensitivity to bright light and glare.”

More articles on supply chain:
Allergan recalls 170k birth control samples with placebo pills in wrong order
Fortune’s 5 most influential pharmaceutical distributors and PBMs
FDA OKs Xeljanz for ulcerative colitis

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.